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Abstract Spinocerebellar ataxia 3 (SCA3) is a genetic
disorder resulting from the expansion of the CAG repeats
in the ATXN3 gene. The pathogenesis of SCA3 is based on
the toxic function of the mutant ataxin-3 protein, but the
exact mechanism of the disease remains elusive. Various
types of transgenic mouse models explore different aspects
of SCA3 pathogenesis, but a knock-in humanized mouse
has not yet been created. The initial aim of this study was
to generate an ataxin-3 humanized mouse model using a
knock-in strategy. The human cDNA for ataxin-3 con-
taining 69 CAG repeats was cloned from SCA3 patient and
introduced into the mouse ataxin-3 locus at exon 2, delet-
ing it along with exon 3 and intron 2. Although the human
transgene was inserted correctly, the resulting mice
acquired the knock-out properties and did not express
ataxin-3 protein in any analyzed tissues, as conﬁrmed by
western blot and immunohistochemistry. Analyses of RNA
expression revealed that the entire locus consisting of
human and mouse exons was expressed and alternatively
spliced. We detected mRNA isoforms composed of exon 1
spliced with mouse exon 4 or with human exon 7. After
applying 37 PCR cycles, we also detected a very low level
of the correct exon 1/exon 2 isoform. Additionally, we
conﬁrmed by bioinformatic analysis that the structure and
power of the splicing site between mouse intron 1 and
human exon 2 (the targeted locus) was not changed com-
pared with the native mouse locus. We hypothesized that
these splicing aberrations result from the deletion of further
splicing sites and the presence of a strong splicing site in
exon 4, which was conﬁrmed by bioinformatic analysis.
In summary, we created a functional ataxin-3 knock-out
mouse model that is viable and fertile and does not present
a reduced life span. Our work provides new insights into
the splicing characteristics of the Atxn3 gene and provides
useful information for future attempts to create knock-in
SCA3 models.
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Background
Spinocerebellar ataxia 3 (SCA3), which is also called
Machado–Joseph disease (MJD), is a dominant genetic
disorder that results from the expansion of the CAG repeats
in the coding sequence of the ATXN3 gene (Coutinho and
Andrade 1978; Kawaguchi et al. 1994) (MJD and ATXN3:
OMIM 109150 and 607047). The majority of patients suf-
fering from SCA3 carry one allele of ATXN3 with 60–82
CAG repeats and a second allele containing the normal
number of repeats, which is usually between 13 and 41
(Kawaguchi et al. 1994; Giunti et al. 1995). Expression of
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toms, typically in the third or fourth decade of life. SCA3
patients commonly suffer from motor and mental abnor-
malities, such as gait ataxia, ocular symptoms, and demen-
tia (Coutinho et al. 1982; Ishikawa et al. 2002; Kawai et al.
2004; Franc ¸a et al. 2007, 2008; Riess et al. 2008).
Although the relevant pathogenesis of SCA3 is based on
the toxic function of the mutant ataxin-3 protein, the exact
mechanism of disease remains elusive (Paulson 2007; Riess
et al. 2008). Expanded CAG repeats in the ataxin-3 mRNA
result in long polyglutamine (polyQ) tracts within the pro-
tein, resulting in protein misfolding. These changes may
affect features, such as protein binding, subcellular locali-
zation of the protein, and its degradation and elimination
fromthecell(Chowetal.2004;LessingandBonini2008).In
the misfolded protein,the polyglutamine chains are exposed
and can scaffold normal and mutant ataxin-3 as well as
important proteins, such as histone acetylases, deacetylases,
transcription factors, and the proteasome complex (Evert
etal.2006;BilenandBonini2007;Ferroetal.2007;Lessing
andBonini2008;Jiaetal.2008).Inturn,thescaffoldingand
subsequent events can affect gene expression, change the
cellular localization of different proteins, and lead to the
dysfunction of the protein elimination pathway in cells.
Knock-out, transgenic, and YAC transgenic mouse
models have been created to explore various aspects of
SCA3 pathogenesis. The transgenic animals in these stud-
ies were generated by the random integration of a transgene
in the form of an artiﬁcial construct that contained either
full-length human ataxin-3 cDNA or some fragment of the
gene. The transgene was usually driven by a different
promoter, such as a Purkinje-speciﬁc L7 promoter (Ikeda
et al. 1996). Model animals containing the polyQ fragment
of ataxin-3 develop the disease phenotype. However, ani-
mals with full-length mutant ataxin-3 protein are viable and
healthy. To explain this surprising result, the authors
hypothesized that the lack of proteolytic cleavage of the
mutant transgenic protein is necessary to produce the dis-
ease phenotype. Consistent with this hypothesis, transgenic
mice expressing higher levels of ataxin-3 with expanded
repeats developed a phenotype reminiscent of SCA3 and
had a cleavage fragment in brain (Goti et al. 2004). The
YAC transgenic animals created by Cemal et al. (2002)
expressed human ataxin-3 driven by its native gene pro-
moter. This strategy resulted in a close reproduction of
human SCA3 pathology in the mouse model, a result that is
probably due to the similar expression pattern of the mutant
ataxin-3 protein. This result reveals the importance of non-
coding sequences and native protein processing in the onset
and progression of SCA3. The impact of the cellular
localization of ataxin-3 on the pathology of SCA3 has been
investigated using mouse models generated by introducing
transgenes coupled to either a nuclear localization signal
(NLS) or a nuclear export signal (NES) (Bichelmeier et al.
2007). The resulting animals containing the NLS transgene
showed markedly enhanced SCA3 symptoms relative to
animals containing the NES transgene. The role of
co-chaperones and the ubiquitin ligase C-terminus of the
Hsp70-interacting protein in enhancing disease progression
and increasing aggregate formation was explored in the
SCA3 mouse model (Williams et al. 2009) created by Goti
et al. (2004). Recently, Boy et al. (2009) provided evidence
that the behavioral SCA3 phenotype could be reversible by
creating an inducible model of SCA3 using the Tet-off
system. The same group demonstrated the late-onset
transgenic model with ataxin-3 driven by huntingtin pro-
moter (Boy et al. 2010). The mouse model where ataxin-3
is driven by the CMV promoter does not show intranuclear
inclusions (Silva-Fernandes et al. 2010). In addition, one
knock-out model of mouse ataxin-3 has been created.
These animals exhibit increased levels of total protein
ubiquitination and minor behavioral changes, but they are
viable and fertile (Schmitt et al. 2007).
We have created a K300 transgenic mouse model that
lacks functional ataxin-3 protein expression conﬁrmed by
western blotting and immunohistochemistry. The mouse
model was generated as a result of a knock-in strategy
wherein human ataxin-3 cDNA was inserted into the mouse
ataxin-3 locus. The ﬁnal mouse model exhibited the pres-
ence of several splice forms of ataxin-3 mRNA and the
presence of deleted non-functional ataxin-3 proteins that
were detected at very low levels only when using a massive
excess of protein extract. The correctly spliced mRNA
isoform containing mouse exon 1/human exons was
detected at very low levels using PCR with increased
sensitivity, but the protein of interest was not detected even
when using a massive excess of protein extract for
immunoblotting. The most prominent mRNA isoforms
detected in mut/mut animals were mouse ataxin-3 missing
exons 2 and 3 and the mRNA comprising mouse exon 1
spliced with human exon 7. We conclude that the reason
for the lack of ataxin-3 protein expression was the occur-
rence of alternative splicing events at the Atxn3 locus after
targeting. In summary, these transgenic mice are functional
knock-out of ataxin-3, are viable and fertile, and do not
have a reduced life span.
Methods
Animals and Cell Line
The animals were kept under standard conditions with a
12-h light/dark cycle and water and food ad libitum. The
animals were marked via a toe-clipping method, and the
tissue from this procedure was used for genotyping
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123analyses. The animals were sacriﬁced by placing them in a
70% CO2 atmosphere. All procedures and animal handling
were carried out to minimize animal stress and were
approved and monitored by the Local Ethical Commission
for Animal Experiments in Poznan. The N171-82Q
(Schilling et al. 1999) and B6.129P2-Htttm2Detl/J (Lin
et al. 2001) mouse models were obtained from The Jackson
Laboratory (Bar Harbor, Maine, USA).
Primary human ﬁbroblasts (cell line number: GM06153)
were obtained from the Coriell Institute for Medical
Research (Camden, NJ, USA). The cells were propagated in
DMEM supplemented with 10% fetal bovine serum (Invit-
rogen; Carlsbad, USA) at 37C in a 5% CO2 atmosphere.
Strategy and Generation of the K300 Mouse Model
The K300 (ICS internal project number) SCA3 transgenic
mouse model was generated at the Institut Clinique de la
Souris (ICS) in Strasbourg, France, as part of the ‘‘RNA
Interference Technology as Human Therapeutic Tool’’
(RIGHT) project. The human mutant ataxin-3 cDNA
sequence containing 69 CAG repeats was cloned from total
mRNA isolated from human ﬁbroblasts (GM06153) that
were derived from a patient suffering from SCA3. The
mouse model was generated using a knock-in strategy that
introduced a human cDNA sequence that spanned exons 2
through 11 of the human mutant ataxin-3 mRNA into the
mouse ataxin-3 gene. To inactivate the mouse ataxin-3
gene, the strategy was designed to preserve mouse exon 1
and intron 1 in the native gene and introduce human exons
2–11 in place of mouse exons 2 and 3 (Fig. 1). In the ﬁnal
construct used for homologous recombination, an SV40
polyadenylation signal and a loxP-NEO
R-loxP cassette
were introduced downstream of the human ataxin-3 cDNA.
The homologous arms present in the construct were 4.5 and
3.5 kb for the 50 and 30 arms, respectively. The construct
was subsequently introduced into Sv129/Pas embryonic
stem cells, and clones were selected based on neomycin
resistance and tested for proper recombination by PCR and
sequencing. The clones were then injected into blastocysts
of C57BL/6 mice to obtain chimeras, which were then bred
to obtain transgenic animals. The loxP-NEO
R-loxP cassette
was excised by breeding the transgenic animals with
animals expressing Cre recombinase.
Genotyping Strategies
All animals were genotyped using a protocol based on the
facts that the mutant allele does not contain an intron
between exons 2 and 3 and that the sequences of both
exons 2 and 3 are identical between humans and mice.
Therefore, primers binding to both human and mouse
exons 2 and 3 would generate PCR products that differed
only by the length of the intron. The PCR product lengths
resulting from this approach would be 376 bp in wild-type
(wt/wt) animals, 150 bp in mutant (mut/mut) animals, and
both products in wt/mut animals. The sequences of primers
for genotyping are as follows: forward exon 2 CAAGG
Fig. 1 The structure of the mouse ataxin-3 gene and the targeting
strategy. The targeting vector containing human exons 2–11 (gray)
terminated by the necessary pA signals (black) was inserted into the
mouse Atxn3 locus by replacing and deleting mouse exon 2, intron 2,
and exon 3 (a). The targeted mouse Atxn3 locus contains mouse exon
1, intron 1, human exons, and mouse exons 4–11. The arrows indicate
primers used for the ampliﬁcation and veriﬁcation of 50 and 30 ends by
sequencing. The sequencing analysis of PCR products from the 50 and
30 ends revealed correct insertion of the transgene (b). The targeted
clones demonstrated the expression of the normal mouse ataxin-3 and
human mutant ataxin-3 protein detected by immunoblotting (c). The
mouse exons are numbered with italic and human exons with regular
font type
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123AGAATATTTTAGCCCTGT, reverse exon 3 GCCGCT
GTCATCCATATTTCCA.
DNA Isolation and PCR
Total DNA was isolated from mouse toes using an Invisorb
tissue mini kit (Invitek; Berlin, Germany) according to the
manufacturer’s instructions. DNA concentration was esti-
mated using a NanoDrop (Thermo Scientiﬁc; Wilmington,
USA) spectrophotometer. PCR was performed with 1 llo f
template DNA in a total volume of 10 ll that included
6 pmol of the appropriate primers and 0.25 U of recom-
binant GoTaq polymerase (Promega; Madison, USA). PCR
ampliﬁcation included 28 cycles of denaturation at 94C
for 30 s, annealing at 58C for 30 s, and elongation at 72C
for 30 s. Primer sequences and their respective PCR
products are listed in Table 1. The reaction products were
separated on 1.5% agarose gels in TBE buffer and stained
with ethidium bromide.
RNA Isolation and RT–PCR
Total RNA was isolated from whole brain tissue samples
using TRI REAGENT (MRC; Cincinnati, USA) according
to the manufacturer’s instructions. RNA isolation typically
yielded 20 lg of total RNA. The RNA concentration was
measured by a NanoDrop spectrophotometer. One micro-
gram of total RNA was digested by DNase I in a volume of
10 ll at room temperature. After 45 min, the digestion
reaction was stopped by adding 1 ll of 50 mM EDTA. A
total of 10 ll of digested RNA were reverse-transcribed at
42C for 50 min using 200 U of Superscript II (Invitrogen)
and 100 ng of random hexamer primers (Promega) in a
ﬁnal volume of 20 ll. PCR was performed according to the
conditions described above. Prior to each primary tran-
script PCR experiment, the quality of DNase digestion was
assessed by PCR using the following templates: 1 llo f
digested RNA, 1 ll of undigested RNA, and 100 ng of
digested DNA. The quality of the reverse transcription
(RT) reaction was assessed by an ampliﬁcation of the
Gapdh gene.
Immunoblotting Analyses
The tissue samples and primary human ﬁbroblasts
(GM06153) were lysed in a buffer containing 60 mM
TRIS-base, 2% SDS, 10% sucrose, and 2 mM PMSF.
Large tissue pieces were chopped and disrupted by soni-
cation. Protein concentration was estimated using a
NanoDrop spectrophotometer, and 50 and 200 lg of total
protein was diluted in a sample buffer containing
2-mercaptoethanol and boiled for 5 min. The proteins were
separated by SDS–polyacrylamide gel electrophoresis (5%
stacking/12% resolving gel), transferred to nitrocellulose
and stained with Ponceau S solution. The blots were
blocked with 5% nonfat milk in TBS/0.05% Tween 20 and
subsequently incubated for 24 h at 4C with anti-ataxin-3
clone 1H9 (1:3,000; wt epitope E214-L233) primary anti-
body (Millipore; Billerica, USA) and with anti-ubiquitin
(1:300) (Dako; Glostrup, Denmark). The blots were probed
either with combination of biotinylated antibody and
AP-conjugated streptavidin or with the HRP-conjugated
secondary antibody (1:3,000) (Jackson Immuno Research,
Suffolk, UK). The immunoreaction was detected using the
Table 1 Primers
Forward (50-30) Reverse (50-30) Localization of
the PCR product*
Product (bp)
CATGGGGCTTACAAAGTTTGTTTTGACTGC GTGCGATAATCTTCACTAGTAACTCCTCC 50 End of the
transgene (DNA)
278
CCCTTCAACTGTATACCGTGTGCTC CCCCACTCTAAACTGACTGTGGTAG 30 End of the
transgene (DNA)
476
CCAGACAAATAAACATGGAG TGTGGACTATTTTCACACATAC mE1/mE9 823 (wt)
613 (E1/mE4)
CCAGACAAATAAACATGGAG CCCTCTGCAAATCCTCCTCATCT mE1/hE8,mE8 498 (E1/mE4)
234 (E1/hE7)
CCAGACAAATAAACATGGAG CATTCCTGAGCCATCATT mE1/hE8 677 (E1/hE2)
205 (E1/hE7)
GCATCGACCAAAACTTAT TTTCTAAAGACATGGTCACA CAG repeats mE6,
hE6/mE11,hE11
674 (human)
473 (mouse)
The last column shows lengths of the PCR products corresponding to the particular splicing isoform
* m mouse; h human; E# exon number
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with the ECL substrate (GE Healthcare; Uppsala, Sweden).
Immunohistochemistry
The 10-lm coronal mouse brain sections or sections from
testis were cut using a cryostat at -13C and collected on
silanized glass slides. The sections were ﬁxed in cold 4C
acetone for 20 min and stored at -80C or processed
immediately. The sections were permeabilized by incu-
bating in 0.5% Tween 20 in PBS for 10 min in RT and
subsequently blocked by incubating in 2% normal goat
serum for 30 min in PBS. For immunoﬂuorescent staining
of intranuclear inclusions, the K300 and N171/82Q brain
sections were incubated overnight at 4C with primary
rabbit anti-ubiquitin (1:300) (Dako). The Cy-3 anti-rabbit
ﬂuorescent secondary antibodies (Jackson ImmunoRe-
search) were incubated at 1:500 for 2 h at RT in PBS-
Tween 20. The cryosections from testis were incubated
with mouse anti-ataxin-3 antibody (1:500) (Millipore)
overnight at 4C and subsequently detected by 2-h incu-
bation with the appropriate biotinylated secondary Ab and
stained using Vectastain Elite ABC (Vector laboratory,
Burlingame, CA, USA) and the DAB chromogen. The
ﬂuorescent confocal images were acquired using the LSM
510 META system (Zeiss; Poznan, Poland).
Results
Structure of the Targeted Atxn3 Gene
and the Expression of Ataxin-3 in Targeted ES Cells
Prior to the electroporation of ES cells, the entire cassette
used for homologous recombination was sequenced (ICS;
Strasburg). This veriﬁed the correct structure and sequence
(for a description of the cassette, see the Materials and
Methods). Stable ES cell clones were selected, and PCR
and sequencing were performed to detect proper transgene
integration into the Atxn3 gene locus (ICS; Strasburg).
These analyses conﬁrmed that the human cDNA was
inserted at mouse exon 2 and that the mouse genomic
sequence containing exon 2, intron 2, and exon 3 was
deleted. Mouse exon 1 and intron 1 were preserved in the
gene structure and were followed by human exons 2–11
and an SV40 polyadenylation signal. The knock-in tar-
geting strategy of the Atxn3 gene is depicted in Fig. 1a. To
demonstrate the correct positioning of the transgene in the
genome, two distinct pairs of primers were designed to
bind mouse intron 1/human exon 2 (50-ﬂank) and human
exon 10/mouse intron 3 (30-ﬂank). The PCR ampliﬁcation
generated 2 PCR products of 278 bp and 476 bp in length,
corresponding to the expected bp count. The PCR products
generated from the 50 and 30 ends of the construct were
sequenced and revealed the correct insertion of the trans-
gene (Fig. 1b). Mouse exons and introns beyond exon 3
were unchanged.
Additionally, to investigate the ataxin-3 protein
expression in targeted ES cells, the total protein extract was
analyzed by western blotting, and the expression of both
the mouse ataxin-3 protein (41 kDa) and human mutant
ataxin-3 (57 kDa) was detected (Fig. 1c). For a positive
control, the blots of the total protein extracted from
GM06153 SCA3 human ﬁbroblasts revealed a mutant
ataxin-3 band with 69 CAG repeats that had an estimated
molecular weight of 57 kDa.
Animals
The 6 mut/wt animals were generated at ICS as a result of
backcrossing chimeras two times onto the pure C57BL/6J
background resulting in mixed background of 75% C57BL/
25% Sv129/Pas. These animals were exported to Poznan
and used to produce 3 generations of offspring and were
withdrawn from breeding. Next, we have generated
homozygous mut/mut animals that exhibited normal body
posture (Fig. 2a, b) and normal muscle strength assessed
by string test (Fig. 2c–e). To assess life span, 5 mut/wt
animals initially received from ICS were kept, until they
reached 2.5 years of age and then sacriﬁced.
Analyses of the Ataxin-3 Protein in K300 Mouse
Tissues
To investigate the expression of the ataxin-3 protein in the
transgenic mice, total protein was extracted from the
cerebral cortex, skeletal muscles (quadriceps), heart, lungs,
liver, spleen, testis, and GM06153 human ﬁbroblasts as a
positive control and resolved by 12% SDS–PAGE. In wt/wt
animals, the immunoblot analyses revealed a speciﬁc band
representing mouse ataxin-3 with an estimated molecular
weight of 41 kDa that was present at relatively high con-
centrations in testis, cerebral cortex, lungs, liver, and
spleen and was hardly detectable in skeletal muscles and
the heart (Fig. 3a). The band detected in wt/wt mice had a
lower molecular weight than the positive control band of
wt human ataxin-3 (48 kDa). The similar mouse ataxin-3
41-kDa band and the expected human mutant 57-kDa band
were not detected in mut/mut animals in any of the tissues
analyzed (Fig. 3a). Moreover, none of these immunoreac-
tive bands was observed upon increasing the protein load to
200 lg of mut/mut protein extract from cerebral cortex and
testis per lane (Fig. 3b). Additionally, analysis of the
ataxin-3 protein in testis from wt/wt animals revealed an
additional strongly immunoreactive band of 34 kDa that
we describe as ataxin-3 isoform, since it was not present in
58 Neuromol Med (2011) 13:54–65
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total protein extract content to the large amount of 200 lg
per lane, we were able to observe two faint immunoreac-
tive bands of 33 and 26 kDa, respectively, that only
appeared in mut/mut animals, but exclusively in testis and
not in cerebral cortex (Fig. 3b). Note that the apparent
7-kDa molecular weight difference was also present
between mouse ataxin-3 (41 kDa) and the 34-kDa ataxin-3
isoform detected in wt/wt testis.
The Cellular Phenotype of the K300 Mouse
Nuclear inclusions are the hallmark of polyglutamine dis-
orders and are present in both patients and mouse models.
Therefore, we examined the brains of K300 animals for the
presence of intranuclear inclusions by immunoﬂuoro-
chemistry using anti-ubiquitin antibodies in cerebral cortex
and cerebellum of the K300 mut/mut and using N171/82Q
animals as positive controls (Huntington’s disease mouse
model; Schilling et al. 1999). As expected, the cortex
and cerebellum of N171/82Q mice revealed intranuclear
inclusions positive for ubiquitin (Fig. 4a, c). Similar
structures were not detected in cells from cortex or cere-
bellum of K300 mut/mut mice stained with anti-ubiquitin
antibodies (Fig. 4b, d). To demonstrate the loss of ataxin-3
expression, we cryosectioned the testis from K300 mut/
mut animals and wt/wt animals and stained the tissue using
anti-ataxin-3 antibodies and the DAB chromogen. The cells
in testis of wt/wt animals were positively stained for
ataxin-3 (Fig. 4e), and no staining was detected in mut/mut
animals (Fig. 4f).
The knock-out model of mouse ataxin-3 previously
created by Schmitt et al. (2007) exhibited increased levels
of total protein ubiquitination, probably due to the absence
of ataxin-3 leading to a partial loss of bulk cellular ubiq-
uitin-speciﬁc protease activity. To test whether a similar
phenomenon could be observed in K300 animals, we
studied the level of ubiquitinated species in brain tissue
using western blotting. The immunodetection with anti-
ubiquitin antibodies revealed no differences in the total
level of ubiquitin in mut/mut compared with wt/wt animals
(Fig. 4g).
Fig. 2 Body posture and string test of K300 mice. The 6-month-old
K300 mut/mut exhibited normal body posture with normal pelvis
elevation and lack of hunchback (a) like the 6-months-old non-
transgenic wt/wt animal (b). The muscle strength was assessed by
placing the mouse from above with only front paws on the
horizontally stretched string for 2 min. The K300 mut/mut animal
(c) and wt/wt animal (d) were able to lift and grab the string with hind
limbs. As positive control we used the Huntington’s disease knock-in
mouse model (mut/wt; 150CAG) generated by Lin et al. (2001) and
supplied by Jackson Laboratory (B6.129P2-Htt
tm2Detl/J). The HD
knock-in mouse at similar age was hardly able to touch the string with
hind limbs and often fell down (e)
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of K300 Animals
The examination of protein expression and the lack of
ataxin-3 staining in tissue provided strong indications that
the expression from the targeted Atxn3 allele was defective,
leading us to hypothesize that the allele had acquired
knock-out properties. To further investigate this issue and
the possible reasons for the lack of ataxin-3 protein in
mice, we tested Atxn3 mRNA expression. Since the
expression of ataxin-3 and the pathology of SCA3 are both
located in the brain, we initially examined the expression
of ataxin-3 mRNA in brain samples from transgenic ani-
mals, including samples of cortex, cerebellum, pons, and
basal ganglia. A representative set of RT–PCR results
generated using tissue samples from the cerebral cortex
was selected for this publication and described below.
RT–PCR results from other brain regions yielded similar
results (data not shown).
Speciﬁc primers were used to selectively detect either
human (mut allele) or mouse ataxin-3 mRNA (wt allele)
(Fig. 5). A single forward primer was designed for exon 1 to
bind mRNA from both wt and mut alleles. The human-
speciﬁc reverse primer was designed to bind exon 8 and
generate a mut-speciﬁc PCR product of 677 bp. The mouse-
speciﬁc reverse primer was designed to bind exon 9 and
generate a wt-speciﬁc product of 823 bp. Interestingly, the
standard 28 PCR cycles did not allow us to detect the mut-
speciﬁc product (677 bp) using the RT template from mut/
mut or wt/mut animals. A detailed description of the detec-
tion of the mut-speciﬁc product and other splice forms is
provided below. Unexpectedly, the wt-speciﬁc product was
presentinmut/mutanimals,butwasshorterthanthewt/wt—
speciﬁc product (613 bp). Wt-speciﬁc RT–PCR of wt/mut
animalsrevealedtwoproducts,the613-bpproductdescribed
above and the expected 823-bp wt-speciﬁc product. As
expected, the wt-speciﬁc product was present in wt/wt ani-
mals(Fig. 5).Thepresenceoftheshort613-bpwtproductin
themut/mutanimalswasevenmorepuzzling,asthisproduct
appeared to be shortened by the combined length of mouse
exons 2 and 3, which had been deleted. Sequencing analysis
demonstratedthatthesequenceofmouseexon1wasdirectly
linked with mouse exon 4 and subsequent exons (Fig. 6).
TheseresultsindicatethattheaberrantsplicingofthemRNA
expressedfromthetargetedallelemayberesponsibleforthe
lack of ataxin-3 protein expression.
Fig. 3 Immunoblot analysis of ataxin-3 expression in tissues of K300
mice. Total protein was extracted from brain, lung, heart, spleen,
testis, skeletal muscle, and liver samples collected from transgenic
(mut/mut) and wild-type (wt/wt) animals as well as from a primary
culture of human SCA3 ﬁbroblasts (GM06153), which was used as a
positive control. The extracts were resolved by 12% SDS/PAGE, and
the blot was stained with a polyclonal antibody for ataxin-3. In wt/wt
animals, the analysis revealed a mouse ataxin-3 41-kDa band present
at relatively high concentrations in testis, cerebral cortex, lungs, liver,
and spleen that was hardly detectable in skeletal muscles and heart. A
similar 41-kDa band and the human mutant ataxin-3 57-kDa band
were not detected in any tissues from mut/mut animals. Additionally,
we detected a 34-kDa band of the ataxin-3 isoform in testis from
wt/wt animals. This isoform was not present in the testis of mut/mut
animals (a). Upon increasing the total protein load to 200 lg per lane,
we were still unable to detect a human mutant ataxin-3 57-kDa band,
but we did detect two faint immunoreactive bands of 33 and 26 kDa,
only in testis of mut/mut animals. The apparent 7-kDa molecular
weight difference between the 33- and 26-kDa bands is the same as
that between mouse ataxin-3 (41 kDa) and the 34-kDa ataxin-3
isoform detected in wt/wt testis (b)
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Ataxin-3 Knock-Out Mouse
We investigated whether the mouse exon 1/exon 4 splicing
form was the only splicing event that hindered the splicing
of mouse exon 1 with human exons. We also asked whether
a similar splicing isoform was present in the K300 model in
tissues other than brain, and for this purpose, we analyzed
the total mRNA from skeletal muscles, heart, lungs, liver,
spleen, and testis of mut/mut animals. We detected two
major splice forms in all analyzed tissues of K300 animals
except liver where the exon 1/human exon 7 isoform was
not present (Fig. 6). As previously demonstrated for the
cerebral cortex, we detected the presence of the mouse
exon 1/exon 4 splice variant that was strongly expressed in
testis and lungs and was less pronounced in liver, skeletal
muscles, heart, and spleen (Fig. 6b; data shown for testis
and cortex). Moreover, we detected a PCR product repre-
senting a splice variant containing mouse exon 1 and part
of human exon 7 (Fig. 6c). This splice variant was spliced
at the splicing site that was inside human exon 7, but it was
in frame, so that the putative protein would be the exon 2–6
deleted form of ataxin-3. A particularly pronounced
expression of the mouse exon 1/human exon 7 isoform was
detected in testis, and this isoform was detected in other
tissues at lower levels. Because some splicing events and
the resulting splice variants may be rare, we decided to
increase the sensitivity of our detection by increasing the
Fig. 4 The cellular phenotype of the K300 mouse model. The
cryosections prepared from cerebellum and cerebral cortex were
stained using anti-ubiquitin Ab, and confocal images were acquired.
The intranuclear inclusions were not detected in cryosections from
K300 mut/mut mouse brain (b, d). The positive control brains from
N171/82Q HD animals revealed a large number of intranuclear
inclusions positive for ubiquitin in both cerebellum and cerebral cortex
(a, c). Additionally, the cryosections from testis of K300 mut/mut
and wt/wt animals were stained using anti-ataxin-3 antibodies and the
DAB chromogen, and the nuclei were counterstained with hematox-
ylin dye. Testis from K300 mut/mut animals did not stain positively
for ataxin-3, and testis of wt/wt animals exhibited speciﬁc, positive
brown staining for ataxin-3 in a subset of cells in testis (e, f). The
immunoblotting of total proteins with anti-ubiquitin antibodies
revealed no difference in the levels of total ubiquitin in mut/mut
compared with wt/wt animals (g)
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123number of PCR cycles. Indeed, in cortex and testis using 37
PCR cycles, we were able to detect a very faint signal of
the 677 bp band representing the mut/mut—speciﬁc splice
variant containing mouse exon 1 and the human exons. The
variety of reverse primers binding to all exons of the
ataxin-3 gene (2–11), and the forward primer for mouse
exon 1, were used to detect splicing events throughout the
primary transcript of the targeted allele. Therefore, Fig. 6
summarizes the experiments detecting splice variants with
three primers binding to exon 1, mouse exon 8, and human
exon 8 that best reﬂect the presence of all splice variants in
K300 tissues. Based on our experiments, we estimate that
the cellular levels of splice variants had the following
relationship: the 1/4 splice variant was the most prominent,
the level of the 1/7 variant was 10% that of the 1/4 variant,
and the 1/2 variant was hardly detectable.
Discussion
The initial goal of this project was to create a mouse model
of SCA3 using a knock-in strategy that would introduce
human ataxin-3 cDNA into the mouse ataxin-3 gene. In this
approach, intron 1, exon 1, the promoter, and other 50
regulatory sequences were left unmodiﬁed, and the human
ATXN3 cDNA was inserted into mouse exon 2. This allows
the human sequence containing 69 CAG repeats to be
expressed from the native mouse ataxin-3 promoter toge-
ther with other putative natural regulatory sequences, such
as CpG methylation islands located in intron 1. After the
homologous recombination cassette was checked thor-
oughly by sequencing, it was electroporated into ES cells.
The selected clones were screened for proper homologous
cassette recombination, and the clones revealed an exact
insertion of human cDNA at exon 2. Moreover, the
Fig. 5 Expression of ataxin-3 mRNA in brain samples from trans-
genic animals. The 677-bp RT–PCR product, which represents
mRNA containing mouse exon 1 and human exons of ataxin-3, was
initially not detected in the mut/mut and wt/mut animals using the
standard 28 PCR cycles (H). The RT–PCR product that was speciﬁc
for mouse mRNA containing exon 1 was detected in transgenic
animals (mut/mut and wt/mut). The product was shorter by the length
of exons 2 and 3 (lines) and was 613 bp rather than the predicted
823-bp wt product, suggesting the alternative splicing event. H human
ataxin-3 speciﬁc PCR; M mouse ataxin-3 speciﬁc PCR
Fig. 6 Splicing events in mut-mut K300 animals. The diagram
graphically depicts the splicing events, and the primers called F, B,
A1, and A2 used to detect the various mRNA isoforms (a). The mouse
exon 1/exon 4 and the mouse exon 1/human exon 7 isoforms were
detected in cortex, testis, and other tissues (data not shown) and were
conﬁrmed by sequencing (b). The exon 1/exon 2 splice variant
(677 bp) was detected in the brain and testis at very low levels using
primers F/B and using 37 cycles to increase PCR sensitivity. The
205-bp product represents exon 1/human exon 7 isoform (c)
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123targeted ES cells revealed the expression of mutant trans-
gene protein, but the mutant protein was expressed at a
lower level than the native mutant protein in human
ﬁbroblasts and also at a lower level than wt mouse ataxin-
3. The mice were generated, and the transgene was vali-
dated in animals by PCR ampliﬁcation and sequencing of
50 and 30 insert ﬂanks as well as by PCR ampliﬁcation of
the internal transgress region composed of exons 2–9,
conﬁrming correct placement in the genome in vivo.
Analyzing brain, lungs, heart, spleen, testis, muscles, and
liver from the generated animals, we did not detect the
mutant human ataxin-3 protein that was previously detec-
ted in targeted ES cells. Therefore, we increased the sen-
sitivity of our western blotting protocol by increasing the
protein load up to 200 lg, but we were still unable to detect
mutant protein expression. Instead, in testis of mut/mut
mice, we detected very low levels of two proteins that were
much shorter (33 and 26 kDa) than the wt mouse ataxin-3
protein. The apparent molecular weight difference between
the two molecules was 7 kDa, similar to the difference
between wt mouse ataxin-3 protein and the second ataxin-3
protein isoform, with the most pronounced expression in
testis (41 and 34 kDa, respectively). The two isoforms (33
and 26 kDa) were probably proteins with deleted protein
fragments equivalent to the sequences of exons 2 and 3.
The presence of splice variant (exon 1/exon 4) equivalent
to 33-kDa protein was detected in all tissues. The 33-kDa
protein must lack the segment of the catalytic Josephine
domain that spans from amino acids Q9–Q78 and includes
the C14 residue. The substitution of C14 to alanine (C14A)
in wild-type ataxin-3 was previously shown to be sufﬁcient
to render ataxin-3 nonfunctional by abolishing ubiquitin-
speciﬁc protease activity (Burnett et al. 2003).
The presence of the second ataxin-3 protein isoform
(wt: 34 kDa; mut: 26 kDa) detected in testis was not
conﬁrmed by the detection of an equivalent transcript.
Because we screened and designed primers in all exons, the
equivalent transcript would have to appear repeatedly as a
PCR product resulting from many different reverse primers
and the forward primer for exon 1. Therefore, we conclude
that this protein is the ataxin-3 isoform (because it is not
present in mut/mut mice), that it is a proteolytic fragment,
and, being found at relatively high levels, that it is quite
stable and accumulates in testis. Pronounced expression of
a similar peptide was previously reported in C57BL mouse
testis, skeletal muscles, and heart (do Carmo Costa et al.
2004).
Because we did not detect the mutant ataxin-3 protein
using western blotting of the mut/mut protein extract, we
investigated the expression of this protein using immuno-
chemistry. The intranuclear inclusions often appear in the
brains of patients and in mouse models of polyglutamine
diseases and are usually strongly ubiquitinated (Cemal
et al. 2002; Bichelmeier et al. 2007; Alves et al. 2008).
Intranuclear inclusions positive for ubiquitin were not
detected in cerebellum or cerebral cortex of K300 animals,
indicating the lack of mutant ataxin-3 protein accumula-
tion. Moreover, the direct staining of the testis, the most
prominent source of ataxin-3 expression, revealed a com-
plete loss of this protein in mut/mut K300 animals. This
strongly indicates that the targeted allele acquired knock-
out properties and that the mut/mut K300 mice are knock-
out animals. The knock-out of ataxin-3 created by Schmitt
et al. (2007) exhibited enhanced total protein ubiquitina-
tion, but we did not detect this effect in K300 animals.
Since the genome encodes nearly 100 deubiquitinating
enzymes, the changes produced by one of them may be
compensated for by other DUBs.
To determine the reason for the lack of correct protein
expression, we investigated the transcripts of the targeted
Atxn3 locus and the level of ataxin-3 mRNA expression.
Initially, we examined the brain and were not able to detect
a common PCR product representing mRNA that contained
mouse exon 1 and the human exons of ataxin-3. Instead, we
detected human RNA using PCR for expanded repeats
(Suppl. Fig. 1). This indicated that the human transgene
was transcribed. Surprisingly, in homozygous transgenic
animals, but not in wt animals, we detected a PCR product
containing exon 1 that was speciﬁc for mouse mRNA.
However, this PCR product was shorter than the wt product
by the combined length of mouse exons 2 and 3.
Sequencing revealed that mouse exon 1 and the remaining
mouse exons 4–11 were spliced. The presence of a similar
splice variant was recently detected in the blood of healthy
human individuals (Bettencourt et al. 2010). Additionally,
we characterized the primary and mature transcripts and
revealed that the entire locus was expressed, and the cel-
lular levels of both the mouse and the human portions of
the transcript in the mut/mut mouse were relatively high.
The cellular level of human transcript was lower than the
level of mouse transcript, but it was almost twice as high as
the level of primary transcript (Suppl. Fig. 2).
The lack of mutant protein expression may result from
aberrant mRNA splicing in targeted allele where mouse
exons 4–11 are still expressed and induce preferences in
splicing that led to the exclusion of the exon 1/human exon
2 isoform. We investigated the splicing aberrations in the
targeted allele in more detail and found the presence of
another splicing form, the splicing of exon 1 and part of
exon 7. Moreover, both exon 1/exon 4 and exon 1/exon 7
splicing forms were also present in other tissues of the
K300 model. Additionally, we tried to increase the sensi-
tivity of our PCR detection and were able to detect the
expected exon 1/exon 2 splice form at a very low level
after 37 PCR cycles. However, we cannot exclude the
possibility that other splice variants were produced from
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123this targeted allele. In summary, we detected the presence
of three splice variants and observed that the splicing
favored distant splicing acceptor sites, such as mouse
human exon 7 and exon 4, and virtually eliminated splicing
to human exon 2. This situation is surprising since the
splicing acceptor site in exon 2 remained identical to the
mouse sequence up to the 24th nucleotide and contained
only 3 single-nucleotide changes in the ﬁrst 70 nucleotides
of exon 2. We used the SROOGLE webserver, which
scores splice sites according to 9 different algorithms
(Schwartz et al. 2009). This analysis revealed that com-
bining mouse intron 1 and human exon 2 (like the trans-
gene structure) returned exactly the same splice site
characteristics and the same score as the combination of
mouse intron 1 and mouse exon 2. Further bioinformatic
characterization revealed that the mouse or human intron
1/exon 2 splice site was very weak, with a score of 0.78
(human) and 0.52 (mouse), according to the maximum
entropy-based scoring method (Yeo and Burge 2004).
Additionally, the algorithms failed to detect the branching
site in intron 1. Interestingly, the score for the intron 3/exon
4 splice site was 10.55 (mouse; max. entropy). Therefore,
the splicing aberrations present in the targeted allele most
likely did not result from changing the properties of the
natural intron 1/exon 2 splice site. These aberrations may
be attributed to the deletion of splicing sites present in
intron 2, exon 3, and intron 3. The lack of these structures
and therefore the lack of splicing probably exposed the
strong acceptor site in exon 4 to the donor site in exon 1.
Moreover, it is possible that the natural low-efﬁciency
splicing between exons 1 and 2 of the ataxin-3 gene may be
the limiting step that, at least to some extent, regulates the
expression of the protein. These facts provide important
lessons for future attempts to create a knock-in mouse
model of SCA3. The most important conclusion is to avoid
the 50 region of the Atxn3 gene in future knock-in strategies
due to its splicing characteristics, such as week exon
1/exon 2 splicing efﬁciency.
Conclusions
We have attempted to create a K300 SCA3 mice using the
knock-in strategy. The mouse model turned out to be
nonfunctional and lacked ataxin-3 protein expression and
expressed very low levels of nonfunctional proteins. We
have systemically demonstrated the loss of protein
expression in all analyzed tissues and concluded that we
have produced a knock-out of ataxin-3. We have provided
evidence that the reason for the lack of expected protein
expression was the occurrence of intensive splicing events
present in the targeted locus, since the model (mut/mut)
expresses a long primary transcript containing mouse exons
and human exons with CAG repeats. The animals do not
exhibit changes in fertility or life span relative to their non-
transgenic counterparts.
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